SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Monte Rosa Therapeutics, Inc. (GLUE) News

Follow Monte Rosa Therapeutics, Inc. (GLUE) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 19 public stories across 12 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol GLUE Asset equity Sector Markets 90 days 16 Last 9.37 Updated Nov 05, 2026, 07:02 PM UTC Open live news feed Open GLUE chart & news
M Monte Rosa Therapeutics Reports Quarterly Results Monte Rosa Therapeutics reported results for the quarter ended September 30. The supplied text contains no financial figures. EQUITY | Nov 05, 2026, 07:02 PM UTC M Monte Rosa Therapeutics Reports Third-Quarter Earnings Monte Rosa Therapeutics reported third-quarter earnings, according to the headline and available text. EQUITY | Nov 05, 2026, 12:58 PM UTC M Monte Rosa Therapeutics Reports $54.37M Revenue and $0.03 EPS A $50 million Novartis milestone for MRT-6160 drove year-over-year growth in collaboration revenue. The company swung to net income from a year-earlier loss, with higher interest income contributing and higher research a EARNINGS | Nov 05, 2026, 12:26 PM UTC M Monte Rosa Therapeutics Reports Third-Quarter 2026 Results and Business Updates The company said positive GFORCE-1 Phase 1 results showed MRT-8102 reduced key pathogenic drivers of atherosclerotic disease. EQUITY | Nov 05, 2026, 12:19 PM UTC M Monte Rosa to Receive $37.5 Million Novartis Milestone Payment Monte Rosa Therapeutics said it will receive a $37.50 million milestone payment from Novartis for the first patient visit. EQUITY | Oct 28, 2026, 11:05 AM UTC M Monte Rosa Therapeutics Reports Positive Phase 1 MRT-8102 Data Monte Rosa Therapeutics announced positive GFORCE-1 Phase 1 results for MRT-8102, demonstrating approximately 80-90% NEK7 degradation and broad normalization of ASCVD pathogenic drivers, accompanied by a favorable safety EQUITY | Oct 01, 2026, 11:43 AM UTC H Why Vicor Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket Shares of Vicor Corp (NASDAQ: VICR ) rose sharply in pre-market trading after the company raised its third-quarter sequential revenue growth guidance. Vicor raised its third-quarter sequential revenue growth guidance to LIVE | Oct 01, 2026, 08:31 AM UTC H TABLE-Mrt -2026 div forecast Sept 30 (Reuters) -Mrt Inc.CONSOLIDATED EARNINGS ESTIMATES(in billions of yen unless specified)Full year to Full year toDec 31, 2026 Dec 31, 2026LATEST PREVIOUSFORECAST FORECASTAnnual Div 5.00 yen NIL-Q2 Div NIL-Q4 Div… EARNINGS | Sep 30, 2026, 07:01 AM UTC L Wedbush keeps Monte Rosa Therapeutics price target at $27.00 Wedbush maintained its $27.00 per-share price target for Monte Rosa Therapeutics, according to ratings actions cited by Benzinga (via TradingView News). EQUITY | Sep 09, 2026, 12:22 PM UTC M Monte Rosa gets $50 million milestone as Novartis starts Phase 2 Monte Rosa said it received a $50 million milestone payment after Novartis started a Phase 2 study of MRT-6160, also known as DDY391, in Sjögren’s disease. REGULATION | Sep 08, 2026, 11:03 AM UTC M GLUE: Monte Rosa starts Phase 2 study of MRT-6160 GLUE-linked disclosure says Monte Rosa Therapeutics has initiated a Phase 2 clinical study for its VAV1-directed molecular glue degrader MRT-6160 (DDY391). EQUITY | Sep 08, 2026, 11:00 AM UTC L Monte Rosa reports inducement grants under Nasdaq Rule 5635(c)(4) Monte Rosa Therapeutics, Inc. says it has reported inducement grants under Nasdaq Listing Rule 5635(c)(4). EQUITY | Sep 02, 2026, 08:14 PM UTC L GLUE/Monte Rosa reports Nasdaq Rule 5635(c)(4) inducement grants GLUE says Monte Rosa reported inducement grants under Nasdaq Listing Rule 5635(c)(4). EQUITY | Sep 02, 2026, 08:01 PM UTC L Monte Rosa Therapeutics management to participate in investor conferences Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) said management will participate in upcoming investor conferences, with a webcast of the fireside chat planned. EQUITY | Sep 01, 2026, 11:08 AM UTC L GLUE: Monte Rosa Therapeutics to participate in investor conferences Monte Rosa Therapeutics plans to participate in upcoming investor conferences. EQUITY | Sep 01, 2026, 11:00 AM UTC L Monte Rosa Therapeutics doses first patient in Phase 2 prostate study Monte Rosa Therapeutics announces first patient dosed in MODeFIRe-1, a Phase 2 study of MRT-2359 in combination with apalutamide in AR mutation-positive metastatic castration-resistant prostate cancer. EQUITY | Aug 24, 2026, 11:00 AM UTC L GLUE - Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates GLUE - Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates EARNINGS | Aug 06, 2026, 11:00 AM UTC L GLUE PT raised from $30 to $40, maintains Buy @ JEFF GLUE PT raised from $30 to $40, maintains Buy @ JEFF EQUITY | Jul 27, 2026, 01:20 PM UTC L Guggenheim Maintains Buy on Monte Rosa Therapeutics, Raises Price Target to $35 Guggenheim analyst Michael Schmidt maintains Monte Rosa Therapeutics (NASDAQ: GLUE ) with a Buy and raises the price target from $30 to $35. EQUITY | Jun 30, 2026, 01:54 PM UTC